Allovir, Inc.: management transactions · United States · SEC (Form 4)

About Allovir, Inc.

AlloVir, Inc. (ALVR) is a U.S.-based biopharmaceutical company that has been listed on the NASDAQ market in the United States. Founded in August 2013, the company built its identity around an allogeneic, off-the-shelf virus-specific T-cell (VST) platform aimed at restoring immunity in patients with severe viral diseases, particularly immunocompromised patients such as transplant recipients. Its corporate headquarters are in Lexington, Massachusetts. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1754068/000119312525019332/d888593ds4a.htm?utm_source=openai)) For much of its history, AlloVir’s pipeline centered on posoleucel (ALVR105), a multi-virus VST therapy designed to target adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, HHV-6 and JC virus. The company also developed ALVR106 for respiratory viral diseases, along with additional VST candidates. Strategically, this positioned AlloVir as a highly specialized player in a niche immunotherapy segment, differentiated by its platform approach, its potential for “off-the-shelf” deployment, and its focus on medically severe viral complications with limited treatment options. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1754068/000095017025035143/alvr-20241231.htm?utm_source=openai)) From a competitive standpoint, AlloVir’s key strength has been its scientific depth in engineered T-cell therapies and its focus on high-unmet-need indications. At the same time, the investment case has always carried substantial clinical and financing risk. The company has no approved products and no commercial product revenue, and its filings show years of significant losses. More importantly, AlloVir’s recent profile has been reshaped by the merger agreement with Kalaris Therapeutics, which was approved by AlloVir shareholders in March 2025. The combined company is expected to be renamed Kalaris Therapeutics, Inc. and to trade on the Nasdaq Capital Market under the ticker KLRS. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1754068/000119312526177387/d69530dars.pdf)) Recent corporate developments indicate a major strategic transition. The 2025 annual report states that AlloVir had no approved products and generated no product revenue, while also noting that merger-related cash and a 2025 private placement strengthened the balance sheet. It further indicates that TH103 is now the lead product candidate in the post-merger company’s early development stage. For French-speaking investors, ALVR is therefore best understood as a clinical-stage biotech with real platform innovation, but also a history of heavy cash burn, a dependence on external financing, and a corporate trajectory that has shifted away from its original VST-only story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1754068/000119312526177387/d69530dars.pdf))